BETA — Beta Drugs Income Statement
0.000.00%
Last trade - 00:00
- IN₹12.56bn
- IN₹12.48bn
- IN₹2.27bn
- 74
- 12
- 73
- 54
2019 March 31st | 2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IAS | IAS | IAS | IAS | IAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 659 | 908 | 1,161 | 1,838 | 2,271 |
Cost of Revenue | |||||
Gross Profit | 246 | 361 | 439 | 716 | 971 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 569 | 765 | 982 | 1,484 | 1,841 |
Operating Profit | 90.3 | 143 | 179 | 354 | 430 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 79.1 | 120 | 160 | 343 | 411 |
Provision for Income Taxes | |||||
Net Income After Taxes | 80.4 | 94.2 | 117 | 248 | 307 |
Net Income Before Extraordinary Items | |||||
Net Income | 80.4 | 94.2 | 117 | 248 | 307 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 80.4 | 94.2 | 117 | 248 | 307 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 9.3 | 9.81 | 12.2 | 25.8 | 32 |